Scilex Holding (SCLX) Other Non-Current Assets (2021)
Scilex Holding (SCLX) posted quarterly Other Non-Current Assets of $8.1 million for Q4 2021, little changed quarter-over-quarter from $8.1 million in Q3 2021.
Scilex Holding (SCLX) Other Non-Current Assets (2021) Analysis & Trends
Scilex Holding's Other Non-Current Assets history runs 1 years deep, the most recent figure standing at $8.1 million for Q4 2021.
- In Q4 2021, Other Non-Current Assets changed N/A year-over-year to $8.1 million; the TTM figure through Dec 2021 stood at $8.1 million (changed N/A YoY), while the FY2021 annual figure was $8.1 million, changed N/A from the prior year.
- Other Non-Current Assets for Q4 2021 stood at $8.1 million, roughly flat from $8.1 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $8.1 million in Q1 2021, with the low at $8.1 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.73 Bn | 631.97 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 469.89 Bn | 463.32 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 377.61 Bn | 370.47 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 303.24 Bn | 295.55 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Astrazeneca | 257.81 Bn | 252.91 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.20 Bn | 223.21 Bn | 7.24 Bn | 12.98 Bn |
| 7 | Gilead Sciences | 182.20 Bn | 179.02 Bn | 6.22 Bn | 4.75 Bn |
| 8 | Pfizer | 159.71 Bn | 148.02 Bn | 10.94 Bn | 9.94 Bn |
| 9 | Gsk | 106.41 Bn | 102.24 Bn | 8.24 Bn | 3.56 Bn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 8.12 Mn |
| Sep 30, 2021 | 8.12 Mn |
| Jun 30, 2021 | 8.12 Mn |
| Mar 31, 2021 | 8.12 Mn |